tiprankstipranks
Trending News
More News >
Bod Australia Ltd (AU:BOD)
ASX:BOD
Australian Market

Bod Australia Ltd (BOD) AI Stock Analysis

Compare
3 Followers

Top Page

AU

Bod Australia Ltd

(Sydney:BOD)

Rating:39Underperform
Price Target:
Bod Australia Ltd faces significant financial and operational challenges with declining revenues, persistent losses, and negative equity. Technical analysis indicates overbought conditions without clear upward momentum, while valuation metrics are unfavorable due to a negative P/E ratio. These factors suggest a high-risk profile, resulting in a low overall stock score.

Bod Australia Ltd (BOD) vs. iShares MSCI Australia ETF (EWA)

Bod Australia Ltd Business Overview & Revenue Model

Company DescriptionBod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. The company operates through three segments: Medical, Over The Counter (OTC) Cannabidiol/Hemp, and OTC Herbals. It engages in the development and manufacture of cannabidiol and hemp products for consumers; and development and distribution of therapeutics medicinal cannabis products for medical markets. The company provides Flexofytol, an anti-inflammatory derived from a scientifically validated and clinically trialed turmeric extract that helps in improving joint health, limiting the ageing of cartilage, and reducing inflammation caused by mild arthritis; and Sedistress, a passion flower extract that reduces the symptoms of stress, anxiety, and insomnia. The company was formerly known as Bod Australia Limited and changed its name to Bod Science Limited in December 2022. Bod Science Limited was incorporated in 2014 and is based in Double Bay, Australia.
How the Company Makes MoneyBod Australia Ltd generates revenue through a diversified business model centered around the production and sale of health and wellness products. The company earns money primarily by selling its range of nutraceuticals and skincare products through various distribution channels, including retail partnerships, online sales, and direct-to-consumer platforms. Additionally, BOD benefits from strategic partnerships and licensing agreements with leading companies in the pharmaceutical and cosmetics industries, which expand its market reach and enhance its product offerings. Further contributing to its revenue are research and development collaborations that potentially lead to licensing deals and royalties. BOD's focus on high-quality, scientifically-proven products helps it maintain a competitive edge and attract a loyal customer base, thereby driving its financial performance.

Bod Australia Ltd Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
875.56K1.72M3.42M6.58M5.01M
Gross Profit
-2.08M-3.08M498.15K2.66M1.14M
EBIT
-4.96M-7.45M-5.89M-4.11M-3.67M
EBITDA
-8.03M-7.98M-5.48M-3.95M-4.00M
Net Income Common Stockholders
-6.41M-7.95M-5.41M-4.23M-4.82M
Balance SheetCash, Cash Equivalents and Short-Term Investments
434.40K2.03M3.67M8.05M6.39M
Total Assets
2.31M3.50M5.31M10.35M8.91M
Total Debt
1.83M963.13K0.000.000.00
Net Debt
1.40M-1.07M-3.67M-8.05M-6.39M
Total Liabilities
7.63M4.21M1.85M1.69M4.11M
Stockholders Equity
-5.32M-703.36K3.47M8.66M4.81M
Cash FlowFree Cash Flow
-928.17K-5.83M-4.38M-5.86M-3.68M
Operating Cash Flow
-913.98K-5.68M-4.18M-5.83M-3.22M
Investing Cash Flow
-1.94M-289.61K-207.44K-26.87K-463.58K
Financing Cash Flow
764.83K4.14M0.007.50M7.23M

Bod Australia Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.02
Price Trends
50DMA
0.02
Negative
100DMA
0.02
Negative
200DMA
0.02
Negative
Market Momentum
MACD
>-0.01
Neutral
RSI
100.00
Negative
STOCH
-133.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BOD, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of -133.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BOD.

Bod Australia Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
$5.25B3.24-45.38%2.81%16.79%-0.06%
AUBOD
39
Underperform
AU$4.26M
-49.04%32.85%
$2.01M-21.29%
$5.66M-164.01%
AUAVE
46
Neutral
AU$12.69M-64.72%139.19%33.33%
AUAGH
45
Neutral
AU$21.39M-218.38%-14.30%29.69%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:BOD
Bod Australia Ltd
0.02
0.00
0.00%
ELLXF
Elixinol Wellness
0.01
-0.02
-66.67%
CNGGF
Cann Group
0.02
-0.03
-60.00%
AU:AVE
Avecho Biotechnology Limited
AU:AGH
Althea Group Holdings Ltd.
0.02
>-0.01
-33.33%

Bod Australia Ltd Corporate Events

Bod Science Limited Announces Change in Principal Place of Business
May 7, 2025

Bod Science Limited has announced a change in its registered office and principal place of business to a new address in Sydney, Australia. This move, approved by the Deed Administrator, reflects the company’s ongoing restructuring efforts under a Deed of Company Arrangement. The change is part of Bod’s strategic initiatives to strengthen its operational framework and potentially improve its market positioning.

Bod Science Limited Announces Change in Company Secretary
May 6, 2025

Bod Science Limited has announced a change in its company secretary, with Carlie Hodges resigning and Joanne Patterson being appointed as her replacement. This change occurs as the company continues to operate under a Deed of Company Arrangement, reflecting ongoing restructuring efforts. The appointment of a new company secretary may impact the company’s administrative operations and stakeholder relations as it navigates its current financial and strategic challenges.

Bod Science Limited Advances Corporate Restructuring with Biortica Acquisition
Apr 9, 2025

Bod Science Limited has entered into a Deed of Company Arrangement with Biortica Agrimed Limited, which includes a Share Purchase Agreement to acquire Biortica’s shares. The completion of this arrangement is contingent on meeting certain conditions, including shareholder approvals and compliance with ASX requirements. The company reported a net cash inflow from operating activities of $42k for Q3 FY2025, with customer receipts increasing significantly due to new product introductions. The arrangement and financial updates reflect Bod’s strategic efforts to stabilize and grow its operations amid ongoing corporate restructuring.

Bod Science Limited Extends DOCA Period Amid ASX Compliance Delays
Mar 19, 2025

Bod Science Limited is undergoing a Deed of Company Arrangement (DOCA) with Biortica Agrimed Limited, which was executed in April 2024. The DOCA period has been extended to June 2025 due to delays in meeting ASX requirements, and an extraordinary general meeting will be scheduled once conditions are met.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.